Eliquis

Product manufactured by Redpharm Drug, Inc.

Application Nr Approved Date Route Status External Links
NDA202155 None Oral None Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

1 Indications And Usage 1.1 Reduction Of Risk Of Stroke And Systemic Embolism In Nonvalvular Atrial Fibrillation Eliquis ® (Apixaban) Is Indicated To Reduce The Risk Of Stroke And Systemic Embolism In Patients With Nonvalvular Atrial Fibrillation. 1.2 Prophylaxis Of Deep Vein Thrombosis Following Hip Or Knee Replacement Surgery Eliquis Is Indicated For The Prophylaxis Of Deep Vein Thrombosis (Dvt), Which May Lead To Pulmonary Embolism (Pe), In Patients Who Have Undergone Hip Or Knee Replacement Surgery. 1.3 Treatment Of Deep Vein Thrombosis Eliquis Is Indicated For The Treatment Of Dvt. 1.4 Treatment Of Pulmonary Embolism Eliquis Is Indicated For The Treatment Of Pe. 1.5 Reduction In The Risk Of Recurrence Of Dvt And Pe Eliquis Is Indicated To Reduce The Risk Of Recurrent Dvt And Pe Following Initial Therapy.

All Formulated Excipients (0 Total)

None

Active Ingredients ( 1 Total)

Name Structure ZINC ID(s)
1. Apixaban APIXABAN ZINC11677837

Comments